BCL-3 was demonstrated to bind to β-catenin; RNAi-mediated BCL-3 suppression reduced β-catenin/T-cell factor-dependent transcription and the expression of intestinal stem cell genes and Wnt targets LGR5 and ASCL2, both widely accepted colorectal cancer stem cell markers (92–96). This evidence concerns the gene BCL3 and colorectal cancer.